L. Popławska

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2022, Scientific Reports.

Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis

W. Jędrzejczak, W. Jędrzejczak, A. Dmoszyńska, 2014, Chemotherapy.

Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy

Alina Macovei, G. Mihaylov, T. Csoszi, 2016, Wiener klinische Wochenschrift.

Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis

P. Boguradzki, W. Knopińska-Posłuszny, J. Walewski, 2013, Annals of Hematology.

[A rare CD5-positive subgroup of diffuse large B-cell lymphoma - clinical, morphological and immunophenotypic features in Polish patients].

M. Ziarkiewicz, B. Ziarkiewicz-Wróblewska, B. Gierej, 2016, Polish journal of pathology : official journal of the Polish Society of Pathologists.

Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs

M. Mikuła, J. Ostrowski, P. Rutkowski, 2021, BioMed research international.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma

J. Zaucha, J. Walewski, A. Pluta, 2022, British journal of haematology.

Angiogenesis in CD5-positive Diffuse Large B Cell Lymphoma: A Morphometric Analysis.

M. Ziarkiewicz, E. Wolińska, B. Ziarkiewicz-Wróblewska, 2016, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

Increased risk of gastrointestinal lymphoma in carriers of the 657del5 NBS1 gene mutation

K. Sperling, R. Varon, O. Mioduszewska, 2006, International journal of cancer.

Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including recent COVID‐19 pandemic experience

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2023, British journal of haematology.

90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment.

A. Hubalewska-Dydejczyk, A. Sowa-Staszczak, A. Skotnicki, 2006 .

Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group

J. Drozd-Sokołowska, B. Puła, E. Lech-Maranda, 2023, Annals of Hematology.